The proposed acquisition of LENSAR, Inc. by Alcon has been abandoned after intervention from the Federal Trade Commission.
The transaction, originally announced in 2025 and valued at up to approximately $430 million, would have combined two of the leading providers of femtosecond laser-assisted cataract surgery (FLACS) systems. These systems are used in advanced cataract procedures that rely on laser precision rather than traditional surgical methods. The deal included LENSAR’s ALLY robotic cataract laser system and associated software technologies, which Alcon sought to integrate into its global ophthalmic equipment portfolio.
However, the FTC raised concerns that the merger would substantially lessen competition in the market for FLACS devices. According to the agency, Alcon and LENSAR were the two biggest competitors in this segment and had been engaged in direct rivalry that delivered tangible benefits to both surgeons and patients. This competition had reportedly driven down prices and accelerated innovation in surgical technologies.
The FTC’s Bureau of Competition concluded that eliminating this rivalry would likely lead to higher prices and reduced incentives for technological advancement. The agency indicated it was prepared to seek an injunction to block the transaction, citing strong evidence of potential consumer harm. Faced with the prospect of litigation and the difficulty of securing regulatory approval within the agreed timeframe, the parties opted to terminate the merger agreement.
The collapse of the deal highlights the increasing willingness of U.S. antitrust authorities to challenge mergers in specialized healthcare technology markets, particularly where innovation and pricing dynamics are closely linked to competition between a small number of firms. It also reflects a broader enforcement trend emphasizing the protection of dynamic competition, not only current price effects but also future innovation pathways.
Following the termination, LENSAR will retain a $10 million deposit paid under the merger agreement and has indicated it will continue to pursue its standalone growth strategy. The company remains focused on expanding the adoption of its ALLY system, which integrates robotic technology, advanced imaging, and artificial intelligence to improve surgical outcomes and efficiency in cataract procedures.
Cataract surgery represents one of the most common medical procedures globally, with millions performed each year. As demand grows alongside aging populations, the development and commercialization of advanced surgical technologies have become increasingly important. The FTC’s intervention suggests that regulators view competition in this space as critical to ensuring continued improvements in quality, accessibility, and cost.
The decision to abandon the merger ultimately preserves the competitive structure of the FLACS market, maintaining the conditions that have driven recent price competition and innovation. At the same time, it sends a clear signal that acquisitions aimed at consolidating leadership positions in highly concentrated, innovation-driven healthcare markets are likely to face close regulatory scrutiny.